Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Substance-Related Disorders 1Neoplasms 1Fatigue 1Caregiver Burden 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Acceptance and Commitment Therapy × 1 year × Clear all
NCT05643027 2026-05-14

ACTION

Dana-Farber Cancer Institute

Phase NA Completed
40 enrolled

Neoplasms, Substance-Related Disorders

NCT07329868 2026-01-09

Comparison of ACT and CBSM for Caregivers in Cancer

Ardakan University

Phase NA Completed
66 enrolled

Caregiver Burden, Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡